Afinitor and Heavy or prolong menstrual bleeding - a phase IV clinical study of FDA data

Summary:

Heavy or prolong menstrual bleeding is reported as a side effect among people who take Afinitor (everolimus), especially for people who are 40-49 old, have been taking the drug for 1 - 6 months also take Lexapro, and have Angiomyolipoma.

The phase IV clinical study analyzes which people have Heavy or prolong menstrual bleeding when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Heavy or prolong menstrual bleeding?

Heavy or prolong menstrual bleeding is found to be associated with 745 drugs and 1,264 conditions by eHealthMe. Check the latest studies of Heavy or prolong menstrual bleeding.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

41,609 people reported to have side effects when taking Afinitor.
Among them, 52 people (0.12%) have Heavy or prolong menstrual bleeding.

Could Afinitor cause Heavy or prolong menstrual bleeding?

Among these 52 people:

How long have people been on Afinitor when they have Heavy or prolong menstrual bleeding? *

What is the age of people who have Heavy or prolong menstrual bleeding when taking Afinitor? *

What are other drugs people take besides Afinitor? *

What are other side effects people have besides Heavy or prolong menstrual bleeding? *

Fatigue (feeling of tiredness): 19 people, 36.54%
Stomatitis (inflammation of mucous membrane of mouth): 18 people, 34.62%
Hair Loss: 11 people, 21.15%
Diarrhea: 11 people, 21.15%
Nausea (feeling of having an urge to vomit): 11 people, 21.15%
High Blood Pressure: 10 people, 19.23%
Peripheral Swelling: 10 people, 19.23%
Fever: 10 people, 19.23%
Weight Decreased: 9 people, 17.31%
High Blood Cholesterol: 9 people, 17.31%

What are the existing conditions these people have? *

Angiomyolipoma (most common benign tumour of the kidney): 23 people, 44.23%
Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 12 people, 23.08%
Neuroendocrine Tumor: 6 people, 11.54%
Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 6 people, 11.54%
Brain Neoplasm Benign (non-cancerous tumour of brain): 4 people, 7.69%
Pancreatic Neuroendocrine Tumor: 3 people, 5.77%
Depression: 3 people, 5.77%
Hyperthyroidism (over activity of the thyroid gland): 2 people, 3.85%
Arrhythmias (irregular heartbeat): 2 people, 3.85%
Heart Disease: 2 people, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and have Heavy or prolong menstrual bleeding?

- Check whether Heavy or prolong menstrual bleeding is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afinitor:

Afinitor (41,680 reports)

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heavy or prolong menstrual bleeding:

Heavy or prolong menstrual bleeding (745 drugs)

Browse all the conditions that are associated with Heavy or prolong menstrual bleeding:

Heavy or prolong menstrual bleeding (1,264 conditions)

Related publications that referenced our studies

Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.